Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell...
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
About this item
Full title
Author / Creator
Jin, Nan , Keam, Bhumsuk , Cho, Janice , Lee, Michelle J , Kim, Hye Ryun , Torosyan, Hayarpi , Jura, Natalia , Ng, Patrick Ks , Mills, Gordon B , Li, Hua , Zeng, Yan , Barbash, Zohar , Tarcic, Gabi , Kang, Hyunseok , Bauman, Julie E , Kim, Mi-Ok , VanLandingham, Nathan K , Swaney, Danielle L , Krogan, Nevan J , Johnson, Daniel E and Grandis, Jennifer R
Publisher
United States: American Society for Clinical Investigation
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Society for Clinical Investigation
Subjects
More information
Scope and Contents
Contents
Alpelisib selectively inhibits the p110α catalytic subunit of PI3Kα and is approved for treatment of breast cancers harboring canonical PIK3CA mutations. In head and neck squamous cell carcinoma (HNSCC), 63% of PIK3CA mutations occur at canonical hotspots. The oncogenic role of the remaining 37% of PIK3CA noncanonical mutations is incompletely unde...
Alternative Titles
Full title
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Authors, Artists and Contributors
Author / Creator
Keam, Bhumsuk
Cho, Janice
Lee, Michelle J
Kim, Hye Ryun
Torosyan, Hayarpi
Jura, Natalia
Ng, Patrick Ks
Mills, Gordon B
Li, Hua
Zeng, Yan
Barbash, Zohar
Tarcic, Gabi
Kang, Hyunseok
Bauman, Julie E
Kim, Mi-Ok
VanLandingham, Nathan K
Swaney, Danielle L
Krogan, Nevan J
Johnson, Daniel E
Grandis, Jennifer R
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8592538
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8592538
Other Identifiers
ISSN
1558-8238,0021-9738
E-ISSN
1558-8238
DOI
10.1172/JCI150335
